Clinical Trial Update: Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies [Phase 1]

View source ↗

Summary

Phase Ib study of TNO155 in combination with Spartalizumab or Ribociclib in selected malignancies was terminated, involving multiple indications including non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastrointestinal Stromal Tumor
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Ribociclib (ribociclib)
• Spartalizumab (spartalizumab)
• TNO155 (TNO155)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: TERMINATED